The prevalence of cannabis use in patients with psychotic mental illness is known to be high and is suspected to exacerbate symptoms and worsen prognosis. We aimed to evaluate evidence of antipsychotic efficacy in reducing the burden of psychotic symptoms and cannabis use in individuals with psychotic mental illness and co-morbid cannabis use. A systematic review was conducted of antipsychotic treatment in those with psychotic mental illness and co-morbid cannabis use. Quality of evidence for each study and outcomes were rated using the ‘GRADE’ approach. Twenty-two studies were identified: 13 experimental and 9 observational, including a total sample of 1543 patients, 761 of whom had a diagnosed cannabis use disorder. The most frequent antipsychotics compared were risperidone, olanzapine and clozapine with olanzapine, risperidone and haloperidol. No clear differences between antipsychotics were demonstrated. Future studies are needed to confirm whether clozapine is superior to other antipsychotics in reducing cannabis use.
AkereleELevinFR (2007) Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia. Am J Addict16: 260–268.
2.
BakerALHidesLLubmanDI (2010) Treatment of cannabis use among people with psychotic or depressive disorders: a systematic review. J Clin Psychiatry71: 247–254.
3.
BakerALThorntonLKHidesL. (2012) Treatment of cannabis use among people with psychotic disorders: a critical review of randomised controlled trials. Curr Pharm Des18: 4923–4937.
4.
BalshemHHelfandMSchünemannHJ. (2011) GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology64: 401–406.
5.
BarnettJHWernersUSecherSM. (2007) Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry190: 515–520.
6.
BarrowcloughCHaddockGWykesT. (2010) Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: randomised controlled trial. BMJ341: c6325.
7.
BerkMBrookSTrandafirAI (1999) A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. Int Clin Psychopharmacol14: 177–180.
8.
BerkSBrookFNurM (2000) Risperidone compared to haloperidol in cannabis-induced psychotic disorder: a double blind randomized controlled trial. Int J Psychiatry Clin Pract4: 139–142.
9.
BhattacharyyaSAtakanZMartin-SantosR. (2012a) Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of delta-9-tetrahydrocannabinol on midbrain and striatal function. Mol Psychiatry17: 1152–1155.
10.
BhattacharyyaSAtakanZMartin-SantosR. (2015a) Impairment of inhibitory control processing related to acute psychotomimetic effects of cannabis. Eur Neuropsychopharmacol25: 26–37.
11.
BhattacharyyaSCrippaJAAllenP. (2012b) Induction of psychosis by Δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry69: 27–36.
12.
BhattacharyyaSFalkenbergIMartin-SantosR. (2015b) Cannabinoid modulation of functional connectivity within regions processing attentional salience. Neuropsychopharmacology40: 1343–52.
13.
BhattacharyyaSFusar-PoliPBorgwardtS. (2009) Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry66: 442–451.
14.
BhattacharyyaSIyegbeCAtakanZ. (2014) Protein kinase B (AKT1) genotype mediates sensitivity to cannabis-induced impairments in psychomotor control. Psychol Med44: 3315–3328.
15.
BossongMGvan BerckelBNBoellaardR. (2009) Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology34: 759–766.
16.
BrookesSTWhitleyEPetersTJ. (2001) Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess5: 1–56.
17.
BrunetteMFDawsonRO’KeefeCD. (2011) A randomized trial of clozapine versus other antipsychotics for cannabis use disorder in patients with schizophrenia. J Dual Diagn7: 50–63.
18.
BrunetteMFDrakeREXieH. (2006) Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull32: 637–643.
19.
CasciniFAielloCDi TannaG (2012) Increasing delta-9-tetrahydrocannabinol (Δ-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev5: 32–40.
20.
CaspariD (1999) Cannabis and schizophrenia: results of a follow-up study. Eur Arch Psychiatry Clin Neurosci249: 45–49.
21.
ConleyRRKellyDLGaleEA (1998) Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophr Res33: 95–101.
22.
DegenhardtLHallW (2001) The association between psychosis and problematical drug use among Australian adults: findings from the National Survey of Mental Health and Well-Being. Psychol Med31: 659–668.
23.
DegenhardtLTennantCGilmourS. (2007) The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. Psychol Med37: 927–934.
24.
DesseillesMMathotFDesseillesM (2008) Aripiprazole diminishes cannabis use in schizophrenia. J Neuropsychiatry Clin Neurosci20: 117–118.
25.
DrakeREXieHMcHugoGJ. (2000) The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull26: 441–449.
26.
EllenbergSSTempleR (2000) Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Ann Intern Med133: 464–470.
27.
FotiDJKotovRGueyLT. (2010) Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry167: 987–993.
28.
GrechAVan OsJJonesPB. (2005) Cannabis use and outcome of recent onset psychosis. Eur Psychiatry20: 349–353.
29.
GreenAIBurgessESDawsonR. (2003) Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res60: 81–85.
30.
GreenAITohenMFHamerRM. (2004) First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res66: 125–135.
31.
GuyattGHOxmanADVistG. (2011) GRADE guidelines: 4. Rating the quality of evidence – study limitations (risk of bias). J Clin Epidemiol64: 407–415.
32.
GuyattGHOxmanADVistGE. (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ336: 924–926.
33.
HarrisAWLargeMMRedoblado-HodgeA. (2010) Clinical and cognitive associations with aggression in the first episode of psychosis. Aust N Z J Psychiatry44: 85–93.
34.
HarrisonIJoyceEMMutsatsaSH. (2008) Naturalistic follow-up of co-morbid substance use in schizophrenia: the West London first-episode study. Psychol Med38: 79–88.
35.
HenquetCvan OsJKuepperR. (2010) Psychosis reactivity to cannabis use in daily life: an experience sampling study. Br J Psychiatry196: 447–453.
36.
HidesLDaweSKavanaghDJ. (2006) Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study. Br J Psychiatry189: 137–143.
37.
HintonMEdwardsJElkinsK. (2007) Reductions in cannabis and other illicit substance use between treatment entry and early recovery in patients with first-episode psychosis. Early Interv Psychiatry1: 259–266.
38.
HjorthøjCFohlmannANordentoftM (2009) Treatment of cannabis use disorders in people with schizophrenia spectrum disorders – a systematic review. Addict Behav34: 520–525.
39.
HuntGESiegfriedNMorleyK. (2014) Psychosocial interventions for people with both severe mental illness and substance misuse. Schizophr Bull40: 18–20.
40.
IsaacMHollowayF (2005) Is cannabis an anti-antipsychotic? The experience in psychiatric intensive care. Hum Psychopharmacol20: 207–210.
41.
KhantzianEJ (1985) The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry142: 1259–1264.
42.
KoskinenJLöhönenJKoponenH. (2010) Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull36: 1115–1130.
43.
KovasznayBFleischerJTanenberg-KarantM. (1997) Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull23: 195–201.
44.
KuepperRvan OsJLiebR. (2011) Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ342: d738.
45.
LazaryJ (2012) Psychopharmacological boundaries of schizophrenia with comorbid cannabis use disorder: a critical review. Curr Pharm Des18: 4890–4896.
46.
LewekeFMPiomelliDPahlischF. (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry2: e94.
47.
LiebermanJATollefsonGTohenM. (2003) Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry160: 1396–1404.
48.
Lingford-HughesARWelchSPetersL. (2012) BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol26: 899–952.
49.
LinszenDHDingemansPMNugterMA. (1997) Patient attributes and expressed emotion as risk factors for psychotic relapse. Schizophr Bull23: 119–130.
50.
LittrellKHPettyRGHilligossNM. (2001) Olanzapine treatment for patients with schizophrenia and substance abuse. J Subst Abuse Treat21: 217–221.
51.
MachielsenMBeduinASDekkerN. (2012) Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. J Psychopharmacol26: 189–195.
52.
MachielsenMWVeltmanDJvan den BrinkW. (2014) The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: an fMRI study. J Psychopharmacol28: 633–642.
53.
Martín-SantosRFagundoABCrippaJA. (2010) Neuroimaging in cannabis use: a systematic review of the literature. Psychol Med40: 383–398.
54.
MorganCJFreemanTPSchaferGL. (2010) Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology35: 1879–1885.
55.
NegreteJCKnappWPDouglasDE. (1986) Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. Psychol Med16: 515–520.
56.
NordströmALFardeLNybergS. (1995) D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry152: 1444–1449.
57.
OxmanADSackettDLGuyattGH. (1993) Users’ guides to the medical literature: I. How to get started. JAMA270: 2093–2095.
58.
PatelRWilsonRJacksonR. (2014) Association of cannabis use with hospital admission and treatment resistance in people with first episode psychosis in South London. Oral presentation at the 9th International Conference on Early Psychosis, Tokyo, Japan, 17–19 November 2014.
59.
PortaNBonetCCoboE (2007) Discordance between reported intention-to-treat and per protocol analyses. J Clin Epidemiol60: 663–669.
60.
PotvinSStipELippO. (2006) Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Curr Med Res Opin22: 1277–1285.
61.
PotvinSStipERoyJY (2004) The effect of quetiapine on cannabis use in 8 psychosis patients with drug dependency. Can J Psychiatry49: 711.
62.
RichardsonWSWilsonMCNishikawaJ. (1995) The well-built clinical question: a key to evidence-based decisions. ACP J Club123: A12–13.
63.
RothwellPM (2005) Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet365: 176–186.
64.
RubioGMartínezIPonceG. (2006) Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry51: 531–539.
65.
SamiMRabinerEABhattacharyyaS (2015) Does cannabis affect dopaminergic signaling in the Human brain? A systematic review of evidence to date. Eur Neuropsychopharmacol25: 1201–1224.
66.
SanLArranzBMartinez-RagaJ (2007) Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders. Eur Addict Res13: 230–243.
67.
SchnellTKoetheDKrasnianskiA. (2014) Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study. Am J Addict23: 308–312.
68.
SchoelerTMonkASamiM. (2015) Differential effects of continued versus discontinued cannabis use on outcome in patients with psychosis: a meta-analysis. Lancet Psychiatry, in press.
69.
SchoelerTPetrosNBehlkeI. (2014) Cannabis use as a predictor for relapse in first episode psychosis: a three-year follow-up study. Oral Abstracts. Early Intervention in Psychiatry8 (Supplement 1): 32–62.
70.
SevySRobinsonDGSundayS. (2011) Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes. Psychiatry Res188: 310–314.
71.
StokesPRMehtaMACurranHV. (2009) Can recreational doses of THC produce significant dopamine release in the human striatum?Neuroimage48: 186–190.
72.
StuytEBSajbelTAAllenMH (2006) Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders. Am J Addict15: 166–173.
73.
TempleREllenbergSS (2000) Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med133: 455–463.
74.
TurkingtonAMulhollandCCRusheTM. (2009) Impact of persistent substance misuse on 1-year outcome in first-episode psychosis. Br J Psychiatry195: 242–248.
75.
UNODC (2013) World Drug Report 2013 (United Nations publication, Sales No. E.13.XI.6).
76.
van NimwegenLJde HaanLvan BeverenNJ. (2008) Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial. Can J Psychiatry53: 400–405.
77.
VerdouxHLiraudFGonzalesB. (2001) Predictors and outcome characteristics associated with suicidal behaviour in early psychosis: a two-year follow-up of first-admitted subjects. Acta Psychiatr Scand103: 347–354.
WelgeJAKeckPE (2003) Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression. Psychopharmacology (Berl)166: 1–10.
80.
WilkinsJN (1997) Pharmacotherapy of schizophrenia patients with comorbid substance abuse. Schizophr Bull23: 215–228.
81.
WoodsSWGueorguievaRVBakerCB. (2005) Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Arch Gen Psychiatry62: 961–970.
82.
WuHEOkusagaOO (2015) Antipsychotic medication-induced dysphoria: its meaning, association with typical vs. atypical medications and impact on adherence. Psychiatr Q86: 199–205.
83.
ZammitSMooreTHLingford-HughesA. (2008) Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry193: 357–363.
84.
ZhornitskySRizkallahEPampoulovaT. (2010) Antipsychotic agents for the treatment of substance use disorders in patients with and without comorbid psychosis. J Clin Psychopharmacol30: 417–424.
85.
ZimmetSVStrousRDBurgessES. (2000) Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol20: 94–98.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
